share_log

榮昌生物:海外監管公告 - 關於2024年向特定對象發行A股股票攤薄即期回報及填補措施與相關承諾的公告

REMEGEN: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 2 00:18
Summary by Moomoo AI
榮昌生物製藥(煙台)股份有限公司(「榮昌生物」)計劃於2024年向特定對象發行A股股票,以增加公司總股本和净资产,並進一步優化在研管線、提升核心競爭力及巩固产品市场地位。根據公司2023年度報告,公司2023年度净利润為負,並預測2024年度净利润將有所增亏、持平或减亏。發行完成後,公司將采取措施以避免即期回報被摊薄,並由控股股东、实际控制人及高级管理人员作出相關承诺。此外,公司強調募集资金投资项目將有利於公司持續健康發展,並符合国家相关产业政策及公司未来发展战略。公告日期為2024年3月30日。
榮昌生物製藥(煙台)股份有限公司(「榮昌生物」)計劃於2024年向特定對象發行A股股票,以增加公司總股本和净资产,並進一步優化在研管線、提升核心競爭力及巩固产品市场地位。根據公司2023年度報告,公司2023年度净利润為負,並預測2024年度净利润將有所增亏、持平或减亏。發行完成後,公司將采取措施以避免即期回報被摊薄,並由控股股东、实际控制人及高级管理人员作出相關承诺。此外,公司強調募集资金投资项目將有利於公司持續健康發展,並符合国家相关产业政策及公司未来发展战略。公告日期為2024年3月30日。
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. (“Wing Cheong Biologics”) plans to issue A shares to selected audiences in 2024 to increase the company's total share capital and net assets, and further optimize its research pipeline, enhance core competitiveness and strengthen its product market position. According to the company's 2023 report, the company's 2023 net profit is negative, and the net profit in 2024 is forecast to increase, level or decrease. Upon completion of the issuance, the Company will take measures to prevent future returns from being diluted, with commitments made by its controlling shareholders, controllers and senior management. In addition, the company emphasizes that the fundraising investment projects will contribute to the company's continued healthy development and comply with the country's relevant industrial policies and the company's future development strategy. The announcement date is 30 March 2024.
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. (“Wing Cheong Biologics”) plans to issue A shares to selected audiences in 2024 to increase the company's total share capital and net assets, and further optimize its research pipeline, enhance core competitiveness and strengthen its product market position. According to the company's 2023 report, the company's 2023 net profit is negative, and the net profit in 2024 is forecast to increase, level or decrease. Upon completion of the issuance, the Company will take measures to prevent future returns from being diluted, with commitments made by its controlling shareholders, controllers and senior management. In addition, the company emphasizes that the fundraising investment projects will contribute to the company's continued healthy development and comply with the country's relevant industrial policies and the company's future development strategy. The announcement date is 30 March 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more